Medical Countermeasures

SESSION 2: MEMBER DISCUSSION

SESSION 5: MEMBER DISCUSSION

DR. GUTMANN:  Good morning, everybody, I'm Amy Gutmann. I’m President of the University of Pennsylvania and Chair of the Presidential Commission for the Study of Bioethical Issues, and I welcome you all here to day two of our 12th meeting of this Commission and happy to do so on behalf of myself and Vice Chair of the Commission and President of Emory University, President Jim Wagner.

SESSION 3: MEMBER DISCUSSION

DR. GUTMANN:  I’m going to ask our commission members to assemble so we can get started, and welcome everybody back from lunch. 

SESSION 4: PHILOSOPHICAL GROUNDING OF THE ETHICAL APPROACH

DR. WAGNER: Let's all gather.

Okay, I believe all who are available here are assembled, and Dr. Beauchamp will join us by video conference.  Tom, can you see and hear us?

DR. BEAUCHAMP:  Yes, I can see and hear you.

SESSION 6: FUTURE TOPICS--INCIDENTAL FINDINGS

DR. WAGNER:  Welcome back, Commissioners. We're about to commence on our final session and what we want to do is talk about a specific future topic, obviously there are many we could pursue, but as you will see, I think we have a special interest, if not obligation to be looking at a future topic on Incidental Findings.

DR. GUTMANN:  Welcome, everybody. I'm Amy Gutmann.  I'm President of the University of Pennsylvania and Chair of the Presidential Commission for the Study of Bioethical Issues. On behalf of myself and our Vice Chair, James Wagner, the President of Emory University, I'd like to welcome you to our 12th meeting.

SESSION 3: MCM USE AND RESEARCH IN A POST-EVENT SCENARIO

DR. WAGNER:  So, let’s get started. 

We are shifting now from, um, uh, pre-event discussions to post event.  MCM use, medical countermeasures use and research and post-event scenarios, and we will again, the format, we’ll ask each of you to make your presentations, and then open it for questions.